Akeso Inc Stock price
Is Akeso Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Akeso Inc Stock Analysis
Analyst Opinions
31 Analysts have issued a Akeso Inc forecast:
Analyst Opinions
31 Analysts have issued a Akeso Inc forecast:
Don't miss a Thing! We will send you all news about Akeso Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong and currently employs 3,529 full-time employees. The company went IPO on 2020-04-24. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The firm's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
| Head office | Cayman Islands |
| CEO | Dr. Xia |
| Employees | 3,761 |
| Website | www.akesobio.com |


